argenx reported third-quarter 2026 global product net sales of VYVGART of $1.7 billion, up 54% year over year and 13% quarter over quarter. Positive Phase 3 ALKIVIA results showed consistent treatment effects in IMNM and dermatomyositis, with an sBLA for IMNM on track for submission by year-end 2026. The company submitted an sBLA for ocular myasthenia gravis to the FDA, and a pediatric gMG sBLA was accepted for priority review with a PDUFA target date in February 2027. Phase 3 EMPASSION topline results for empasiprubart in MMN are expected in December 2026, while FB102 is advancing to Phase 3 in celiac disease. argenx continues to target treating 50,000 patients, securing 10 labeled indications and advancing five candidates into registrational development by 2030.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on manilatimes.net ↗
Keywords
argenxpharmaceuticalsearningsclinical trials
Open a keyword to see other news on the same topic.
Related news
- Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Viking Therapeutics has started two phase 3 trials, SUNRISE-1 and SUNRISE-2, for the oral form of its weight loss drug VK2735, alongside its ongoing injectable phase 3 trials. Investors had been shaken by the phase 2 oral trial (VENTURE-Oral), where 20% of treated participants discontinued due to adverse events and the stock fell sharply, although efficacy over 13 weeks was good. The author argues the phase 3 design is different: 13% of the phase 2 placebo group also stopped due to adverse events, phase 2 used a more aggressive titration, and phase 3 runs 68 weeks. CEO Brian Lian said that in phase 2 patients took 4 tablets that were fairly large, and phase 3 aims for smaller tablets and fewer of them. Phase 3 doses are also lower, at 27.5 mg, 35 mg and 55 mg, compared with 15 mg to 120 mg in phase 2.
- Where Will CRISPR Therapeutics Stock Be in 2030?
Shares of CRISPR Therapeutics have fallen about 47% since mid-October 2021, while the S&P 500 has gained almost 73% as of writing, despite clinical and regulatory progress over the past five years. Casgevy, developed with Vertex Pharmaceuticals, was approved in 2023 and early 2024 for transfusion-dependent beta-thalassemia and sickle cell disease, making it the company's first commercial product and the first approved CRISPR-based gene-editing therapy. Other candidates include CTX310, aimed at lowering LDL cholesterol and triglycerides, where Phase 1 data showed significant decreases in both; zugo-cel for autoimmune diseases and blood cancers; and CTX611, an anticoagulant that could be given twice a year. Casgevy's label now covers patients as young as two, adding about 5,500 U.S. patients at $2.2 million per treatment course. The article warns of possible clinical failures and the costly, one-time nature of many gene-editing therapies, which makes profitability uncertain.
- Cosmos Health Inc .: Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue , U . S . Subscription Growth and Global Expansion
Cosmos Health CEO Greg Siokas wrote to shareholders that preliminary nine-month 2026 revenue was about $54.3 million, up 19%, and the company reaffirmed full-year revenue above $90 million, up about 38%. Fourth-quarter revenue is expected to be about $35.7 million or more, up roughly 81% from the same quarter of 2025, driven by pharmaceutical contract manufacturing and distribution, proprietary brands and U.S. e-commerce. U.S. e-commerce had 8,940 active subscriptions as of October 19, 2026, up 42% in five days, and is expected to generate about $15 million in fourth-quarter revenue. The company also repurchased more than 5.1 million shares for about $1.1 million and set 2029 targets of $200.6 million in revenue and $44.2 million in adjusted EBITDA, with the goal of becoming self-funding by 2027.
- Gilead UC Pill Hits Trial Goal , Stock Still Slips
Gilead Sciences (NASDAQ: GILD) said on 19 October 2026 that its experimental oral ulcerative colitis pill, emvistegrast, met the main goal of the mid-stage SWIFT trial. At the 200mg dose, 66% of patients reached clinical response at Week 12 versus 37% on placebo, and 31% achieved clinical remission versus 8% on placebo. Despite the positive readout, GILD shares closed at $153.555, down 1.42%, on volume of 0.82 times the 20-day average, and RBC Capital Markets had said the data were unlikely to move the stock. The results follow a volatile quarter: Gilead posted a Q2 2026 net loss of $10,496m (EPS -$8.45) versus net income of $2,021m in Q1, though Q2 revenue rose to $7,803m from $6,960m. Gilead has not disclosed a timeline for advancing emvistegrast into late-stage testing.
- Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
Regeneron has lagged broader equities over the past two years mainly because Eylea sales are falling under biosimilar and other competition, although the newer high-dose version is performing well. In the second quarter, revenue rose 17% to $4.3 billion, global Dupixent sales reached $6 billion, up 38%, and collaboration revenue from Sanofi grew 51% to $2.2 billion. Non-GAAP earnings per share rose 11% to $14.29, but combined U.S. Eylea revenue fell 12% to about $1 billion. The author believes Regeneron can navigate the possible biosimilar threat to Dupixent in the early 2030s through a new formulation, replacement medicines in development and its own pipeline, including the weight-loss candidate olatorepatide, and expects competitive returns over the medium term.
- Should You Invest in This Dividend King on the Dip?
Johnson & Johnson (JNJ) shares fell significantly after its third-quarter results, even though the company beat expectations and slightly raised its full-year guidance. Revenue reached $25.4 billion, up 5.9%, while adjusted EPS of $2.59 fell 7.5%, a decline the company attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by Darzalex and Tremfya, but medtech revenue of $8.6 billion, up 2.5%, fell short of expectations and drove the post-earnings dip, with the cardiovascular unit hurt by safety and efficacy concerns about the Impella heart pumps. The article points to new drugs such as ICOTYDE and Imaavy as medium-term growth drivers and says the Ottava robotic surgery device could help medtech recover. The author argues investors should hold the stock for the long term, citing JNJ's 64 consecutive years of dividend increases.
Related markets
Latest news
- Investors are punishing Big Tech's biggest spenders. Meta is the latest casualty.
Meta shares fell more than 7% on Thursday, wiping out about $125 billion in market value and erasing the stock's gain for the year. It was on track for its third straight drop of 5% or more the day after earnings, a first since its 2012 IPO. Revenue rose 26% to $64.6 billion, but Meta raised its full-year expense outlook, narrowed capital spending to $135–145 billion, and unveiled nonvoting shares it can sell to raise money. Analyst Gil Luria of D.A. Davidson said Zuckerberg will need to raise both debt and equity, while the cost of insuring Meta's debt climbed to its highest in months. Luria also said Meta is gaining share from Google and its ad sales are growing strongly; the stock has traded roughly between $500 and $800 since mid-2024, and a weekly close above $800 would signal a breakout while a close below $500 would open the door to a deeper slide.
- Oil Climbs Above $111 as AI Stocks Slide, Dragging the S&P 500 and Global Markets With Them
Brent crude rose 2.6% to $111.66 a barrel, its highest in five months, as AI-linked stocks slid and pulled the Nasdaq down 1.5% and the S&P 500 down 0.8% by mid-morning in New York. Asian markets also fell sharply, with South Korea's Kospi down 3.52%, Japan's Nikkei 225 down 2.65% and Hong Kong's Hang Seng down 3.03%, while China's CSI 300 entered a bear market. Nvidia fell 2.3% and Meta dropped 5.8% after its profit missed forecasts. The 10-year Treasury yield rose to 5.03% from 3.97% before the Iran war, ahead of the Fed's Oct. 28 decision. Citadel founder Ken Griffin said investors are 'almost certainly' in an AI bubble, though he did not tell them to sell.
- Oil Climbs Above $111 as AI Stocks Slide, Dragging the S&P 500 and Global Markets With Them
Brent crude rose 2.6% to $111.66 a barrel, its highest in five months, as AI-linked stocks slid and pulled the Nasdaq down 1.5% and the S&P 500 down 0.8% by mid-morning in New York. Asian markets also fell sharply, with South Korea's Kospi down 3.52%, Japan's Nikkei 225 down 2.65% and Hong Kong's Hang Seng down 3.03%, while China's CSI 300 entered a bear market. Nvidia fell 2.3% and Meta dropped 5.8% after its profit missed forecasts. The 10-year Treasury yield rose to 5.03% from 3.97% before the Iran war, ahead of the Fed's Oct. 28 decision. Citadel founder Ken Griffin said investors are 'almost certainly' in an AI bubble, though he did not tell them to sell.
- We're dipping back into the AI trade with our first data center buy in weeks
Jim Cramer's Charitable Trust is buying 10 shares of GE Vernova (GEV) at about 818 USD, lifting its weighting to about 2.15% from 1.9%, its first data center-related purchase since a Micron buy five weeks ago. The trust is buying into a Thursday sell-off driven by investor concern over how to fund the data center buildout, as cash flows are used up and debt financing grows less attractive, rather than weaker AI demand. GE Vernova was the third-worst S&P 500 performer that day and trades about 12% below its Aug. 24 level, when the trust downgraded it to a 2 amid caution on AI stocks; it has now been upgraded to a 1 to play for a bounce.
- Could Intel be the next trillion-dollar company?
Maverick Capital reportedly expects Intel to become a trillion-dollar company again, citing growing demand for CPUs used in AI inference. One speaker argues the story is compelling, pointing to huge chip demand, Intel's domestic chip production and strong government support, and notes the stock, though pulled back, sits right on its 200-day trend line. The others say they sold Intel long ago or never owned it, preferring holdings such as Nvidia, Broadcom and AMD. They describe a five- to seven-year wait that carried a large opportunity cost.
- Underdog taps zerohash to bring crypto deposits to prediction markets
Prediction market operator Underdog has partnered with zerohash to add cryptocurrency and stablecoin deposits, expected to launch later this year. Eligible users will be able to fund accounts through the app with near-instant transfers around the clock, without managing wallet addresses or choosing blockchain networks. Underdog has not yet said which cryptocurrencies or stablecoins will be supported. The company, founded in 2020, has more than 11 million registered accounts and is being acquired by IG Group for up to $1.3 billion, with closing expected in late 2026 or early 2027. Over the 30 days ending Oct. 21, its trading volume reached $1.4 billion, up 133%, still far behind Kalshi's $81.5 billion and Polymarket's combined $17.2 billion.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.